Abstract
Proteins detectable in peripheral blood may influence COVID-19 susceptibility or severity. However, understanding which circulating proteins are etiologically involved is difficult because their levels may be influenced by COVID-19 itself and also subject to confounding factors. To identify circulating proteins influencing COVID-19 susceptibility and severity we undertook a large-scale two-sample Mendelian randomization (MR) study, since this study design can rapidly scan hundreds of circulating proteins and reduces bias due to confounding and reverse causation. We began by identifying the genetic determinants of 955 circulating proteins in up to 10,708 SARS-CoV-2 uninfected individuals, retaining only single nucleotide polymorphisms near the gene encoded by the circulating protein. We then undertook an MR study to estimate the effect of these proteins on COVID-19 susceptibility and severity using the Host Genetics Initiative. We found that a standard deviation increase in OAS1 levels was associated with reduced COVID-19 death or ventilation (N = 2,972 cases / 284,472 controls; OR = 0.48, P = 7×10−8), COVID-19 hospitalization (N = 6,492 / 1,012,809; OR = 0.60, P = 2×10−7) and COVID-19 susceptibility (N = 17,607 / 1,345,334; OR = 0.81, P = 6×10−5). Results were consistent despite multiple sensitivity analyses probing MR assumptions. OAS1 is an interferon-stimulated gene that promotes viral RNA degradation. Other potentially implicated proteins included IL10RB. Available medicines, such as interferon-beta-1b, increase OAS1 and could be explored for their effect on COVID-19 susceptibility and severity.
Competing Interest Statement
JBR reports investigator-initiated grants from Biogen, Eli Lilly and GlaxoSmithKline, for programs unrelated to the research presented here. JBR is an advisor to GlaxoSmithKline.
Funding Statement
The Richards research group is supported by the Canadian Institutes of Health Research (CIHR: 365825; 409511), the Lady Davis Institute of the Jewish General Hospital, the Canadian Foundation for Innovation (CFI), the NIH Foundation, Cancer Research UK, Genome Quebec, the Public Health Agency of Canada and the Fonds de Recherche Quebec Sante (FRQS). TN is supported by Research Fellowships of Japan Society for the Promotion of Science (JSPS) for Young Scientists. JBR is supported by a FRQS Clinical Research Scholarship. SZ is supported by a CIHR fellowship and a FRQS fellowship. GBL is supported by the a CIHR scholarship, and a joint FRQS and Quebec Ministry of Health and Social Services scholarship. Support from Calcul Quebec and Compute Canada is acknowledged. TwinsUK is funded by the Welcome Trust, Medical Research Council, European Union, the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London. These funding agencies had no role in the design, implementation or interpretation of this study. VM is supported by a Canada Excellence Research Chair. The Kaufmann lab is supported by the CIHR, NIH, CFI, AmFAR and FRQS.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All cohorts contributing data to the COVID-19 Host Genetics Initiative received ethics approval from their respective ethics review board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: The Richards research group is supported by the Canadian Institutes of Health Research (CIHR: 365825; 409511), the Lady Davis Institute of the Jewish General Hospital, the Canadian Foundation for Innovation (CFI), the NIH Foundation, Cancer Research UK, Genome Québec, the Public Health Agency of Canada and the Fonds de Recherche Québec Santé (FRQS). TN is supported by Research Fellowships of Japan Society for the Promotion of Science (JSPS) for Young Scientists. JBR is supported by a FRQS Clinical Research Scholarship. SZ is supported by a CIHR fellowship and a FRQS fellowship. GBL is supported by the a CIHR scholarship, and a joint FRQS and Québec Ministry of Health and Social Services scholarship. Support from Calcul Québec and Compute Canada is acknowledged. TwinsUK is funded by the Welcome Trust, Medical Research Council, European Union, the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust in partnership with King’s College London. These funding agencies had no role in the design, implementation or interpretation of this study. VM is supported by a Canada Excellence Research Chair. The Kaufmann lab is supported by the CIHR, NIH, CFI, AmFAR and FRQS.
Disclosures: JBR has served as an advisor to GlaxoSmithKline and Deerfield Capital.
Data Availability
Data from proteomics studies are available from the referenced peer-reviewed studies or their corresponding authors, as applicable. Summary statistics for the COVID-19 outcomes are publicly available for download on the COVID-19 Host Genetics Initiative website (www.covid19hg.org).
